Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia
In the register
The register attaches this trial to Dutasteride (Avodart / Zagallo) (GSK), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 3
- Sponsor
- Stiefel, a GSK Company
- Participants (registry)
- 117
- Start
- July 2014
- Primary completion
- March 2016
- Study completion
- March 2016
- Last registry update
- October 2018
- Countries
- Chile, Hong Kong, Singapore, South Korea, Taiwan
Conditions studied: Alopecia
Interventions: Dutasteride, Placebo
Other trials of Dutasteride (Avodart / Zagallo)
Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.
Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
- NCT01004809Completed
AVODART® Alopecia Post-marketing Surveillance (PMS)
A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.